Effects of polymorphism of vascular endothelial growth factor A on the prognosis of colorectal cancer patients received fluorouracil based adjuvant chemotherapy

doi:10.12092/j.issn.1009-2501.2018.08.010

Abstract

Abstract:

AIM: To investigate the association between VEGF-A gene polymorphism and prognosis in patients with colorectal cancer. METHODS: This study was a retrospective analysis involved 149 patients with colorectal cancer who were underwent surgical treatment and received fluorouracil based adjuvant chemotherapy. Peripheral blood of the CRC patients was collected before surgery used to extract genomic DNA and the genotyping of -94C>G was carried out with PCR-RFLP. The genotype results of 149 patients were further verified and included in the final analysis. The correlation of -94C>G genotype and other variables was analyzed by logistic regression model. The univariate analysis of genotype and prognosis was carried out by Kaplan-Meier survival analysis, and multivariates were adjusted by Cox regression analysis.RESULTS:The prevalence of -94C>G in VEGF-A among the Chinese population are as follows: the GG genotype 62 cases (41.6%), CG genotype 61 cases (40.9%) and CC genotype 26 cases (17.4%), minimum allele frequency was 0.38. The distribution of three genotypes in accordance with Hardy-Weinberg Equilibrium (P=0.113). There were no statistical differences in the distribution of the three genotypes in baseline clinical data. The survival analysis of patients with different genotypes found that the 5 years OS rates of patients with CC genotype was significantly lower, which was statistically significant compared with those of GG/CG genotypes (P=0.022). Adjusted in multivariate Cox regression analysis, CC genotype was an independent factor for OS (OR=3.76, P=0.015). CONCLUSION: Among patients with colorectal cancer, the mutant homozygous CC genotype of VEGF-A -94C>G has independent influence on the prognosis of CRC patients.

Key words: colorectal cancer, vascular endothelial growth factor A, polymorphism, prognosis

CLC Number:

R735

LI Xiaojie,ZHANG Shengwei,WANG Huasheng,WANG Dong, MEI Jiazhuan, DENG Yewei. Effects of polymorphism of vascular endothelial growth factor A on the prognosis of colorectal cancer patients received fluorouracil based adjuvant chemotherapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 900-904.

References

［1］Navarro M, Nicolas A, Ferrandez A, et al. Colorectal cancer population screening programs worldwide in 2016: An update［J］. World J Gastroenterol, 2017, 23(20): 3632-3642.
［2］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115-132.
［3］Wu M, Xiong H, Xu Y, et al. Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis［J］. Br J Ophthalmol, 2017, 101(7): 976-984.
［4］陈冲, 章树业, 荀静娜, 等. KIR-HLA基因多态性与散发性急性戊型肝炎的关系［J］. 临床肝胆病杂志, 2017, 33(3): 462-465.
［5］Perez-Ramirez C, Canadas-Garre M, Alnatsha A, et al. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients［J］. Pharmacogenomics J, 2018. doi: 10.1038/s41397-018-0014-8.
［6］肖鹏, 梅家转, 白桦, 等. 细胞色素P450 1A1基因多态性对奥沙利铂联合卡培他滨方案治疗结直肠癌患者临床疗效的影响［J］. 中国临床药理学与治疗学, 2018, 23(2): 159-164.
［7］Jannuzzi AT,Ozhan G,Yanar HT,et al.VEGF gene polymorphisms and susceptibility to colorectal cancer［J］.Genet Test Mol Biomarkers,2015,19(3):133-137.
［8］Sun W, Wang X, Li J, et al. MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway［J］. Cell Death Dis, 2018, 9(4): 438.
［9］Becherirat S, Valamanesh F, Karimi M, et al. Discontinuous schedule of bevacizumab in colorectal cancer induces accelerated tumor growth and phenotypic changes［J］. Transl Oncol, 2018, 11(2): 406-415.
［10］ Kim JG, Chae YS, Sohn SK, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer［J］. Clin Cancer Res, 2008, 14(1): 62-66.
［11］Wong SCC, Cheung MT, Luk LLY, et al. Prognostic significance of Cytokeratin 20-positive lymph node vascular endothelial growth factor A mRNA and chromodomain helicase DNA binding protein 4 in pN0 colorectal cancer patients［J］. Oncotarget, 2018, 9(6): 6737-6751.
［12］Chae YS, Kim JG, Sohn SK, et al. Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer［J］. J Korean Med Sci, 2008, 23(3): 421-427.
［13］Jang MJ, Kim JW, Jeon YJ, et al. Prognostic significance of vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer［J］. Int J Clin Oncol, 2013, 18(6): 1032-1041.
［14］Hansen TF, Garm Spindler KL, Andersen RF, et al. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer［J］. Pharmacogenomics J, 2011, 11(1): 53-60.
［15］Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature［J］. Br J Cancer, 2006, 94(12): 1823-1832.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[4]	ZHOU Jing, ZHOU Chen, LIAO Ke, QIU Ailin, DONG Weilei, GUO Zifen. Correlation between progesterone receptor G1978T polymorphism and endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 400-406.
[5]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[6]	WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan. Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
[7]	HUANG Kaige, XU Qinhua, WANG Wei. Interaction effect and predictive efficacy of blood glucose and blood calcium on the prognosis of patients with acute severe pancreatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1227-1234.
[8]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[9]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[10]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[11]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[12]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[13]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[14]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[15]	CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177.